01.18.24
Sabinsa has announced that its curcumin ingredient, Curcumin C3 Reduct, has been approved by the ANVISA, the Brazilian national health surveillance agency, for inclusion on its IN28 list.
The approval allows for introduction and commercialization of the ingredient in foods and supplements in the Brazilian market, and was based on a dossier submitted to ANVISA which detailed safety and efficacy information.
C3 Reduct is the only curcumin extract standardized to tetrahydrocurcuminoids, a specific metabolite, on the market, and was given approval at a dosage of 120 mg daily.
Compared to curcuminoids, tetrahydrocurcuminoids are superior for desired biological functions in the body, according to Sabinsa. These cascading antioxidants and major metabolites of curcuminoids are composed of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. As a cascading antioxidant, in comparison to a standalone antioxidant, the ingredient is able to mitigate free radicals for a longer period of time. It is also more bioavailable in the gut compared to parent curcuminoids, enabling delivery through smaller tablets or capsules.
“Many congratulations to our Sabinsa Brazil team for their first approval. This approval of C3 Reduct marks a significant milestone in the supplement market in Brazil, ushering in the era of next-generation curcuminoids,” said Anurag Pande, PhD, VP of scientific affairs at Sabinsa.
“Approval of C3 Reduct by ANVISA on the IN28 list is a testament to the science that Sabinsa has created on curcumin metabolites,” said Muhammed Majeed, PhD, founder of Sabinsa. “This is our first approval in the Brazilian market, with more to follow.”
The approval allows for introduction and commercialization of the ingredient in foods and supplements in the Brazilian market, and was based on a dossier submitted to ANVISA which detailed safety and efficacy information.
C3 Reduct is the only curcumin extract standardized to tetrahydrocurcuminoids, a specific metabolite, on the market, and was given approval at a dosage of 120 mg daily.
Compared to curcuminoids, tetrahydrocurcuminoids are superior for desired biological functions in the body, according to Sabinsa. These cascading antioxidants and major metabolites of curcuminoids are composed of curcumin, demethoxycurcumin, and bisdemethoxycurcumin. As a cascading antioxidant, in comparison to a standalone antioxidant, the ingredient is able to mitigate free radicals for a longer period of time. It is also more bioavailable in the gut compared to parent curcuminoids, enabling delivery through smaller tablets or capsules.
“Many congratulations to our Sabinsa Brazil team for their first approval. This approval of C3 Reduct marks a significant milestone in the supplement market in Brazil, ushering in the era of next-generation curcuminoids,” said Anurag Pande, PhD, VP of scientific affairs at Sabinsa.
“Approval of C3 Reduct by ANVISA on the IN28 list is a testament to the science that Sabinsa has created on curcumin metabolites,” said Muhammed Majeed, PhD, founder of Sabinsa. “This is our first approval in the Brazilian market, with more to follow.”